Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note released on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

APTO has been the topic of a number of other reports. HC Wainwright increased their price target on Aptose Biosciences from $2.00 to $6.00 and gave the stock a “buy” rating in a report on Friday, March 28th. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th.

Aptose Biosciences Price Performance

Aptose Biosciences has a 52 week low of $1.35 and a 52 week high of $50.10. The company has a 50-day simple moving average of $4.41 and a 200-day simple moving average of $7.37. The firm has a market cap of $3.66 million, a P/E ratio of -0.58 and a beta of 1.04.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned about 4.15% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.